Exodus Point Capital Management, LP Alpine Immune Sciences, Inc. Transaction History

Exodus Point Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.75 - $41.6 $813,021 - $1.91 Million	-45,804 Reduced 21.1%	171,251 $6.79 Million
Q3 2023 Nov 09, 2023	BUY	$10.13 - $13.98 $1.56 Million - $2.16 Million	154,216 Added 245.41%	217,055 $2.49 Million
Q2 2023 Aug 10, 2023	BUY	$6.84 - $11.91 $429,818 - $748,412	62,839 New	62,839 $646,000
Q2 2021 Aug 16, 2021	SELL	$8.81 - $15.03 $320,322 - $546,475	-36,359 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$10.02 - $13.92 $539,777 - $749,870	-53,870 Reduced 59.7%	36,359 $385,000
Q4 2020 Feb 16, 2021	BUY	$7.42 - $15.96 $669,499 - $1.44 Million	90,229 New	90,229 $1.14 Million

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.